GlaxoSmithKline Czech Republic - Profit Margins

Net Profit, EBIT & EBITDA as % of Sales
Pharmaceutical | Czech Republic | November 10, 2018
$3.99
Excel Sheet

GlaxoSmithKline Czech Republic made a net profit of CZK CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72% and -14.6%, respectively, when compared to the last year.

This translates into a net margin of 2.26%. Historically, the firm’s net margin reached an all time high of 4.12% in 2011 and an all time low of -0.197% in 2006. The average net margin in the last five years amounted to 2.06%.

On the operating level, EBITDA margin reached 3.10% and EBIT amounted to 3.36% of sales in 2017.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.

Net Margin Unit 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % 10.9% 6.81% 6.14% 6.36% 5.93%
Bayer Czech Republic % 4.96% 2.57% 2.80% 2.64% 2.89%
GlaxoSmithKline Czech Republic % 4.12% 2.86% 2.25% 1.81% 2.85%
Merck Czech Republic % 3.04% 3.62% 1.59% 1.94% 3.71%
Novartis Czech Republic % 1.05% 1.27% 1.29% 1.75% 1.53%
Pfizer Czech Republic % 3.40% 1.54% 2.67% 2.70% 2.41%
Roche Czech Republic % 1.01% 0.794% 2.73% 2.17% 0.936% ...
Sanofi-Aventis Czech Republic % 0.782% 0.626% 0.998% 0.019% 0.889%
Servier Czech Republic % ... ... 3.85% 3.94% 3.09% 2.41%
Walmark % 9.83% -0.140% -0.444% 1.82% -58.0%
AVERAGE % 2.88% 4.35% 2.38% 2.40% 2.43% -3.45% 1.06% 3.38%